Financial Performance - The company's revenue for Q3 2021 reached ¥256,909,136.47, an increase of 49.19% compared to the same period last year[3] - Net profit attributable to shareholders was ¥33,707,925.29, reflecting a growth of 17.06% year-on-year[3] - The net profit excluding non-recurring gains and losses was ¥28,228,859.31, up by 8.59% from the previous year[3] - Total operating revenue for the period reached ¥794,949,444.36, an increase from ¥647,783,882.97 in the previous period, representing a growth of approximately 22.7%[31] - The net profit for the current period is 115,498,710.67, an increase from 105,737,382.21 in the previous period, representing a growth of approximately 7.4%[34] - The total profit for the current period is 142,151,129.24, compared to 126,614,022.41 in the previous period, reflecting an increase of approximately 12.5%[34] - The company reported a total operating profit of 143,456,457.81, an increase from 129,613,820.45 in the previous period[34] - The company reported a net profit margin improvement, with net profit increasing due to higher revenue and controlled costs[31] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,285,094,604.80, representing a 14.17% increase from the end of the previous year[3] - The total assets increased to ¥3,285,094,604.80 from ¥2,877,284,200.91, marking a growth of around 14.1%[31] - Total liabilities decreased to ¥249,514,010.00 from ¥298,959,816.78, a reduction of approximately 16.6%[31] - The equity attributable to shareholders of the parent company rose to ¥3,035,580,594.80 from ¥2,578,324,384.13, an increase of about 17.7%[31] Cash Flow - The company's cash flow from operating activities showed a net decrease of 52.42%, totaling ¥102,751,921.59 year-to-date[11] - The net cash flow from operating activities is 102,751,921.59, down from 215,975,326.69 in the previous period, indicating a decrease of approximately 52.5%[41] - Cash inflow from investment activities totals 1,462,513,124.76, compared to 2,414,944,920.27 in the previous period, a decrease of about 39.4%[41] - The net cash flow from investment activities is 3,719,861.29, a significant improvement from -104,118,463.44 in the previous period[41] - The cash and cash equivalents at the end of the period amount to 341,816,258.94, up from 98,650,340.02 in the previous period[41] Investments and Acquisitions - The company plans to acquire over 51% of Shanghai Gebaide Biotechnology Co., Ltd. after the completion of Phase III clinical trials for a new drug, with an estimated valuation of RMB 480 million[17] - The company invested RMB 10 million to establish Shanghai Kaihe Jiao Medical Technology Co., Ltd., holding a 75% stake, focusing on chiral materials for medical applications[21] - The company has identified potential risks in a private equity fund investment, estimating a recoverable amount of RMB 15,887,200 based on various scenarios[21] - The company’s investment in the private equity fund totaled RMB 100 million, with RMB 864,000 returned by the end of the third quarter of 2021[21] - The company is in the process of acquiring land use rights, with updates to be disclosed as per regulations[21] Shareholder Information - The company’s major shareholders include Mu Jingwei with 125,873,527 shares and Zhang Yanqi with 160,790,370 shares[15] - The company’s total restricted shares at the end of the period were 129,433,306, with 148,425 shares released during the period[16] Operating Costs and Expenses - The company experienced a 33.31% increase in operating costs year-to-date, attributed to higher sales revenue[10] - Total operating costs amounted to ¥663,967,428.89, up from ¥544,345,297.28, indicating an increase of about 22%[31] - Research and development expenses were ¥31,986,225.60, a decrease from ¥41,170,561.35, reflecting a reduction of approximately 22.2%[31] Other Financial Metrics - The weighted average return on equity for the year-to-date was 4.39%, an increase of 0.30% compared to the previous year[3] - The total comprehensive income for the first nine months of 2021 increased by 362.12%, mainly due to the fair value changes of investments[10] - The company has made strategic investments in long-term equity investments, increasing from ¥248,190,000.00 to ¥621,327,500.00, reflecting a growth of approximately 150%[28] - The cash and cash equivalents amounted to RMB 1,332,194,593.06, while trading financial assets decreased to RMB 68,907,408.67 from RMB 114,647,286.37[22] - Accounts receivable stood at RMB 321,481,008.66, slightly up from RMB 319,556,080.91 in the previous period[22] - Cash and cash equivalents increased significantly, with other current assets rising to ¥10,752,772.18 from ¥1,887,773.21, a growth of approximately 469%[28] - The total comprehensive income attributable to the parent company is 105,737,382.21 for the current period[37] - The basic and diluted earnings per share are both 0.1011[37]

Financial Performance - The company's operating revenue for 2020 was ¥908,008,861.43, a decrease of 36.01% compared to ¥1,419,026,170.35 in 2019[21] - The net profit attributable to shareholders for 2020 was ¥106,122,746.60, down 57.72% from ¥250,986,452.13 in the previous year[21] - The net profit after deducting non-recurring gains and losses was ¥95,675,418.53, a decline of 60.90% compared to ¥244,719,614.36 in 2019[21] - The net cash flow from operating activities was ¥250,649,879.39, a decrease of 24.97% from ¥334,085,296.53 in 2019[21] - The basic earnings per share for 2020 was ¥0.1015, down 57.69% from ¥0.2399 in 2019[21] - The total assets at the end of 2020 were ¥2,877,284,200.91, an increase of 1.22% from ¥2,842,499,295.08 at the end of 2019[21] - The net assets attributable to shareholders at the end of 2020 were ¥2,578,324,384.13, a slight increase of 0.34% from ¥2,569,491,637.53 in 2019[21] - The weighted average return on net assets for 2020 was 4.05%, down from 9.76% in 2019, a decrease of 5.71%[21] Revenue and Sales - The industrial segment accounted for 99.90% of total revenue, with a revenue of ¥907,095,032.36, down 35.99% year-over-year[88] - Injection products generated ¥802,754,175.99, representing 88.41% of total revenue, a decline of 39.34% from ¥1,323,301,090.36 in 2019[85] - Sales volume decreased by 36.16% to 40,550,192 units in 2020 from 63,514,926 units in 2019[89] - The gross profit margin for the industrial segment was 80.28%, down 2.21% from the previous year[88] Research and Development - The company is actively enhancing its R&D capabilities and accelerating the development of new products, particularly in the field of traditional Chinese medicine, in response to national health strategies[53] - The company has received five invention patents, one design patent, and one utility model patent, strengthening its intellectual property protection[67] - R&D investment amounted to ¥59,118,892.81, representing 6.51% of operating revenue, a significant increase from 3.85% the previous year[103] - The proportion of R&D personnel increased to 30.07%, up from 28.66% the previous year[103] - The company has ongoing normal operations with no litigation issues reported[115] Product Development and Market Position - The main product, Tanreqing injection, was included in the clinical treatment guidelines for COVID-19, enhancing its market position and contribution to epidemic prevention[37] - The company has developed a product line focusing on respiratory, cardiovascular, and digestive health, enhancing its competitive edge in the pharmaceutical market[36] - The company’s unique product, Tanreqing capsule, has been included in the national medical insurance directory and recommended for COVID-19 treatment in several provinces, enhancing its market potential[54] - The company is focusing on enhancing its internal management systems to improve decision-making efficiency and operational effectiveness[71] Cash Flow and Investments - The company reported a net increase in cash and cash equivalents of ¥246,471,132.86, a significant improvement of 150.25% compared to the previous year[104] - The net cash flow from investment activities increased by 110.86%, reaching ¥65,213,934.39, primarily due to increased capital recovery[104] - The company made a total investment of ¥90,000,000.00 during the reporting period, a 100% increase from the previous year[112] - The company has allocated CNY 4,350 million for the "Modernization of Traditional Chinese Medicine and Other Pharmaceutical Products Construction Project" as part of the excess fundraising[129] Dividend Policy - The company implemented a cash dividend policy, distributing RMB 0.3 per 10 shares, totaling RMB 31,380,000, which represents 100% of the distributable profit[168] - In 2020, the total cash dividend amounted to RMB 31,380,000, representing 29.57% of the net profit attributable to ordinary shareholders[175] - For 2019, the cash dividend was RMB 104,600,000, which accounted for 41.68% of the net profit attributable to ordinary shareholders[172] Compliance and Governance - The company has adhered to commitments regarding non-competition and related transactions during the reporting period[179] - The integrity status of the company and its controlling shareholders was good, with no unfulfilled court judgments or significant overdue debts[193] - There were no significant lawsuits or arbitration matters during the reporting period[191] - The company has maintained a continuous audit service from domestic accounting firms for 13 years[190] Future Outlook and Strategy - The company plans to enhance its R&D capabilities and accelerate the development of new products, particularly in the field of modern Chinese medicine[150] - The company will continue to explore and develop health-related products, aligning with the national "Healthy China" strategy[152] - The company recognizes the risks associated with the pharmaceutical industry, including policy changes and price control measures, which could impact operations[157] - The company is committed to sustainable development through green production practices and optimizing production processes[154]

上海凯宝药业股份有限公司 2021 年第一季度报告全文 上海凯宝药业股份有限公司 2021 年第一季度报告 2021-012 2021 年 04 月 1 上海凯宝药业股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人穆竟伟、主管会计工作负责人张育琴及会计机构负责人(会计主 管人员)李雅茹声明：保证季度报告中财务报表的真实、准确、完整。 2 上海凯宝药业股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | □ 是 √ ...

Financial Performance - Operating revenue for the reporting period was ¥172,201,950.77, a decrease of 37.49% year-on-year[9] - Net profit attributable to shareholders was ¥28,795,802.18, down 47.93% compared to the same period last year[9] - Basic earnings per share were ¥0.0275, a decrease of 48.02% compared to the same period last year[9] - Total operating revenue for the current period was ¥172,201,950.77, a decrease of 37.5% compared to ¥275,480,461.94 in the previous period[56] - Net profit for the current period was ¥28,795,802.18, down 47.9% from ¥55,299,739.61 in the previous period[62] - Basic earnings per share for the current period was ¥0.0275, down from ¥0.0529 in the previous period[65] - The total comprehensive income for the current period was ¥28,795,802.18, compared to ¥55,299,739.61 in the previous period[64] - The net profit for the current period is ¥94,447,793.93, down 53.5% from ¥202,754,981.63 in the previous period[86] - The total profit for the current period is ¥111,115,051.69, a decrease of 53.3% compared to ¥236,940,214.58 in the previous period[83] Cash Flow - Net cash flow from operating activities was ¥103,405,287.46, an increase of 110.75% year-on-year[9] - Cash flow from operating activities generated a net amount of ¥215,975,326.69, an increase of 22.5% from ¥176,370,602.62 in the previous period[89] - The net cash flow from operating activities for the current period is ¥203,462,853.27, an increase of 10.6% compared to ¥184,394,212.15 in the previous period[95] - Cash inflow from investment activities totaled ¥2,414,944,920.27, significantly up from ¥869,233,915.65 in the previous period[92] - The net cash flow from investment activities was negative at -¥104,118,463.44, compared to a positive ¥390,157,005.39 in the previous period[92] - Cash flow from financing activities resulted in a net outflow of -¥69,268,592.11, compared to -¥171,758,827.85 in the previous period, indicating improved cash management[99] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,865,226,751.79, an increase of 0.80% compared to the end of the previous year[9] - Total liabilities rose to ¥294,597,732.05, up from ¥273,007,657.55, representing an increase of around 7.9%[49] - Current liabilities decreased to ¥233,792,455.08 from ¥240,023,695.53, a reduction of approximately 2.5%[46] - Non-current assets totaled ¥663,366,982.92, compared to ¥578,819,158.22, indicating an increase of about 14.6%[49] - The company's accounts payable decreased by 44.81% compared to the beginning of the year, primarily due to a reduction in the procurement of raw materials[23] - Total liabilities amounted to CNY 273,007,657.55, with non-current liabilities totaling CNY 32,983,962.02[109] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 40,282[13] - The top three shareholders held a combined 39.88% of the shares, with Mu Jingwei holding 16.05%[13] - There were no repurchase transactions conducted by the top ten shareholders during the reporting period[20] Government Subsidies and Other Income - The company received government subsidies amounting to ¥15,013,083.11 during the reporting period[9] - Other income increased by 199.70% year-on-year, mainly due to an increase in government subsidies related to daily business activities[24] - Deferred income increased by 117.92% year-on-year, mainly due to an increase in non-recurring government subsidies[23] Research and Development - Research and development expenses increased to ¥17,108,149.46, up 48.5% from ¥11,506,246.51[59] - Research and development expenses for the current period are CNY 41,170,561.35, an increase from CNY 37,634,352.02 in the previous period[73] Tax and Financial Expenses - The company's income tax expense decreased by 42.24% year-on-year, mainly due to a decline in sales revenue[27] - Tax expenses for the current period are CNY 20,876,640.20, down from CNY 36,142,463.38 in the previous period[76] - The company incurred a financial expense of -¥10,633,762.16, an improvement from -¥12,069,159.18 in the previous period[83] Inventory and Current Assets - Inventory was reported at CNY 154,087,957.26, indicating a stable stock position[112] - Current assets totaled CNY 2,017,592,989.97, with cash and cash equivalents at CNY 800,320,107.50[112] Other Financial Metrics - The weighted average return on net assets was 1.13%, down 1.06% year-on-year[9] - The company's retained earnings increased to ¥1,296,084,598.64 from ¥1,294,947,216.43, a slight increase of approximately 0.1%[49] - The total equity attributable to shareholders reached ¥2,570,629,019.74, up from ¥2,569,491,637.53, indicating a marginal increase of about 0.04%[49]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥475,581,932.20, a decrease of 39.64% compared to the same period last year[23]. - The net profit attributable to shareholders of the listed company was ¥76,941,580.03, down 49.71% year-on-year[23]. - The net profit after deducting non-recurring gains and losses was ¥65,462,234.64, a decline of 54.85% compared to the previous year[23]. - The net cash flow from operating activities was ¥112,570,039.23, which is 11.58% lower than the same period last year[23]. - Basic earnings per share were ¥0.0736, a decrease of 49.69% compared to ¥0.1463 in the previous year[23]. - Total assets at the end of the reporting period were ¥2,820,943,901.26, a decrease of 0.76% from the end of the previous year[23]. - The net assets attributable to shareholders of the listed company were ¥2,541,833,217.56, down 1.08% from the previous year[23]. - The company reported a government subsidy of ¥8,944,644.28, which is included in the current profit and loss[27]. - The company's operating revenue for the reporting period was ¥475,581,932.20, a decrease of 39.64% compared to the same period last year, primarily due to the impact of the pandemic[70]. - Operating costs decreased by 37.91% to ¥87,300,435.22, attributed to the decline in sales revenue[70]. - Research and development expenses were ¥24,062,411.89, down 7.91% from the previous year[70]. - The net cash flow from operating activities was ¥112,570,039.23, a decrease of 11.58% due to reduced sales and collection[70]. - The net increase in cash and cash equivalents was ¥210,720,440.90, reflecting a growth of 6.38%[70]. - The company's cash and cash equivalents at the end of the reporting period amounted to ¥1,300,359,760.22, representing 46.10% of total assets, an increase of 19.57% from the previous year[75]. Product Development and Innovation - The main product, Tanreqing injection, is a patented product and has been included in the clinical treatment guidelines for COVID-19 by the National Health Commission[36]. - The company focuses on the development of traditional Chinese medicine and has established three main product lines in respiratory, cardiovascular, and digestive fields[35]. - The subsidiary, Xinyi Pharmaceutical, has a unique product, Qishen Capsule, which is a national new drug for treating coronary heart disease[37]. - The company aims to enhance its innovation capabilities and product quality while accelerating the development of Tanreqing injection and its series[44]. - The company is actively responding to the national "Healthy China Strategy" and aims to explore and develop health-related products[44]. - The pharmaceutical industry in China is experiencing strong demand due to an aging population and the rapid increase of chronic diseases[39]. - The company's main product, Tanreqing injection, is a patented product included in the national medical insurance list, showing significant therapeutic effects and high safety, contributing to its strong market position[45]. - The company has successfully completed the re-registration of 18 products, including Tanreqing injection, and obtained 4 new patents, enhancing its intellectual property protection[56]. - The company is focused on research and innovation, collaborating with universities and research institutions to develop new products and improve production quality[49]. - The company has implemented advanced production technologies, including multi-level ultrafiltration and automated control, to enhance the safety and quality of its injection products[47]. - The company is conducting clinical research on several new drugs, including Dinggui Oil Soft Capsules and Shufeng Zhitong Capsules, with ongoing Phase III studies[67]. - The company is actively expanding its product structure and clinical application range through ongoing research and development efforts[63][67]. - The company plans to enhance its R&D capabilities and accelerate the development of new products to diversify its product line and reduce reliance on a single product[133]. Social Responsibility and Community Engagement - The company actively participated in social responsibility by donating over CNY 4 million in medicines and emergency supplies to key epidemic areas during the COVID-19 pandemic[55]. - The company donated a total of RMB 153,000 for poverty alleviation efforts in the first half of 2020[184]. - The company provided emergency supplies valued at RMB 4.0274 million to pandemic-affected areas during the first half of 2020[184]. - The company has committed to continue its poverty alleviation efforts by leveraging funds and brand effects from being publicly listed[188]. - The company made multiple donations to various charitable foundations, totaling RMB 138,000 in the first half of 2020[184]. - The company has integrated social responsibility into its business operations and management practices[188]. - The company is a leading enterprise in Shanghai's Fengxian District, contributing significantly to local economic development[183]. Risk Management and Compliance - The company faces potential risks in future operations as outlined in the report[6]. - The company is facing significant risks from industry policies, including price reductions and dynamic adjustments to the National Medical Insurance Directory, which could impact operational performance[134]. - The company has identified risks associated with new drug development, including high investment and long cycles, and plans to strengthen its R&D team and collaborate with external research institutions[134]. - The company is actively monitoring and analyzing industry policies to mitigate operational risks arising from regulatory changes[133]. - The company has not faced any major litigation or arbitration matters during the reporting period, reflecting a stable legal environment[145]. - The company has not encountered any issues with the rationality and compliance of its fundraising usage, and information disclosure has been timely, accurate, and complete[100]. - The company has not changed any fundraising projects during the reporting period[101]. - The company has not engaged in derivative investments during the reporting period, indicating a conservative investment strategy[124]. - The company has not sold any significant assets during the reporting period, maintaining its asset base[128]. Fundraising and Investment - The total amount of raised funds is RMB 97,375.76 million, with a cumulative investment of RMB 96,159.12 million as of June 30, 2020[83]. - The company plans to use RMB 78,145.87 million of the excess raised funds, including RMB 14,000.00 million for permanent working capital[84]. - Cumulative usage of raised funds includes RMB 20,700.00 million for the first phase of the modernization of traditional Chinese medicine project[87]. - The company has allocated RMB 18,302.50 million of excess funds for the third phase of the modernization of traditional Chinese medicine project[87]. - As of June 30, 2020, the remaining balance of raised funds is RMB 12,110.61 million, designated for future investment projects[87]. - The company has invested RMB 6,721.00 million in acquiring Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd.[87]. - A total of RMB 13,130.00 million was used to purchase a 20% stake in Shanghai Yizhong Biotechnology Co., Ltd.[87]. - The company has committed to investing RMB 28,700.00 million in the construction of investment projects as disclosed in the prospectus[83]. - The company has verified the fund usage with an accounting firm, ensuring compliance with regulatory requirements[83]. - The company plans to manage remaining funds based on development planning and actual operational needs, submitting plans for board approval[100]. Environmental Management - The company has established two wastewater treatment facilities with a capacity of 1,000 tons per day to ensure compliance with discharge standards[173]. - The company has implemented a nitrogen oxide emission reduction strategy, achieving emissions below 50 mg/m³ through boiler modifications[175]. - The company has received ISO 14001:2015 certification for its environmental management system in October 2019[181].

Product Dependency and Development - The main product, Tanreqing injection, accounts for over 90% of the company's main business revenue, indicating a high dependency on a single product [6]. - The company plans to enhance its R&D capabilities and accelerate the development of new products to diversify its product line and reduce reliance on Tanreqing injection [9]. - The company is actively preparing for the launch of new products and will adopt diversified sales models to ensure successful market entry [9]. - The company aims to strengthen its R&D team and improve project management to mitigate risks associated with new drug development [9]. - The company acknowledges the risks associated with new drug development, including high investment and long cycles, and is committed to controlling these risks [9]. - The company is exploring mergers and acquisitions to leverage research and development resources and accelerate product line expansion [9]. - The company is seeking external opportunities for new product introductions and acquisitions to leverage research and innovation capabilities [155]. Financial Performance - The company's operating revenue for 2019 was CNY 1,419,026,170.35, a decrease of 5.44% compared to CNY 1,500,676,455.17 in 2018 [28]. - The net profit attributable to shareholders for 2019 was CNY 250,986,452.13, representing a growth of 10.66% from CNY 226,812,437.14 in 2018 [28]. - The net cash flow from operating activities increased by 27.34% to CNY 334,085,296.53 in 2019, up from CNY 262,361,430.99 in 2018 [28]. - The total assets at the end of 2019 were CNY 2,842,499,295.08, reflecting a 3.46% increase from CNY 2,747,388,592.99 at the end of 2018 [28]. - The company’s basic earnings per share for 2019 was CNY 0.2369, an increase of 10.65% compared to CNY 0.2141 in 2018 [28]. - The company’s weighted average return on equity for 2019 was 9.76%, up from 9.39% in 2018 [28]. - The company reported a positive profit for the period, with net profit attributable to ordinary shareholders being positive, but no cash dividend distribution plan was proposed [176]. Cash Dividends - The company will distribute a cash dividend of 1 RMB per 10 shares to all shareholders, based on a total share capital of 1,046,000,000 shares [9]. - The cash dividend for 2018 was set at RMB 1 per 10 shares, with a total cash dividend amounting to RMB 104,600,000, representing 41.68% of the net profit attributable to ordinary shareholders [165]. - In 2019, the company proposed a cash dividend of RMB 1 per 10 shares, based on a total share capital of 1,046,000,000 shares, pending shareholder approval [171]. - The total cash dividend for 2019, including other methods, reached RMB 222,019,441.54, which is 88.46% of the net profit attributable to ordinary shareholders [173]. - The cash dividend policy has been executed in compliance with the company's articles of association, ensuring the protection of minority shareholders' rights [162]. Industry Risks and Challenges - The pharmaceutical industry is heavily influenced by national policies, which may pose new risks and challenges to the company's operations [5]. - The company acknowledges risks associated with industry policies, including price reductions and procurement policies that may impact operations [154]. - The company faces risks in new drug development due to high investment, long cycles, and potential market changes that could affect expected benefits [157]. Research and Development - The company aims to accelerate the development of health products in line with the national health strategy, leveraging its unique advantages in traditional Chinese medicine [56]. - The company has established three main product lines in respiratory, cardiovascular, and digestive fields, enhancing its product competitiveness [43]. - Research and development efforts led to the acquisition of 5 invention patents, 3 design patents, and 10 utility model patents during the reporting period [69]. - The company is conducting clinical research on new drug projects, including the "Dinggui Oil Soft Capsule" and "Shufeng Zhitong Capsule," both in Phase III clinical trials [78]. - The company is focusing on optimizing product structure through ongoing research and development of various traditional Chinese medicine formulations [78]. Corporate Governance and Compliance - The company is committed to enhancing its corporate governance and management efficiency through modernized practices and performance assessments [153]. - The company has adhered to all commitments made, with no violations reported during the period [178]. - The current accounting firm, Lixin Certified Public Accountants, has been engaged for 12 consecutive years, with an audit fee of 550,000 yuan for the reporting period [187]. - There were no significant lawsuits or arbitration matters affecting the company during the reporting period [189]. - The company maintained a good integrity status, with no unfulfilled court judgments or significant overdue debts [199]. Market and Sales Strategies - The company emphasizes a specialized clinical academic promotion model, organizing academic meetings to enhance product understanding among professionals [52]. - The company intends to expand its market presence by closely aligning academic promotion with market demand and exploring new sales channels [152]. - The company organized multiple academic promotion activities to enhance brand influence and market competitiveness [70]. - The company has established partnerships with several universities to foster innovation and talent development [60].

Financial Performance - Total revenue for Q1 2020 was ¥293,546,165.70, a decrease of 26.63% compared to ¥400,081,731.87 in the same period last year[9] - Net profit attributable to shareholders was ¥52,708,591.96, down 26.41% from ¥71,629,180.04 year-on-year[9] - Net profit excluding non-recurring gains and losses was ¥47,673,872.64, a decline of 27.60% from ¥65,851,000.69 in the previous year[9] - Basic earnings per share decreased to ¥0.0504, down 26.42% from ¥0.0685 year-on-year[9] - Operating income decreased by 26.63% year-on-year to CNY 293.55 million, primarily due to the impact of the COVID-19 pandemic on terminal demand[29] - Net profit attributable to shareholders decreased by 26.41% year-on-year to CNY 52.71 million, reflecting the overall sales impact from the pandemic[29] - Total operating revenue for the first quarter was CNY 293,546,165.70, a decrease of 26.6% compared to CNY 400,081,731.87 in the same period last year[83] - The company's net profit for the current period is ¥52,708,591.96, a decrease of 26.5% compared to ¥71,629,180.04 in the previous period[89] Cash Flow and Assets - Operating cash flow for the period increased by 31.52% to ¥79,801,253.61, compared to ¥60,675,452.52 in the same period last year[9] - Cash and cash equivalents increased by 54.30% compared to the beginning of the period, mainly due to the recovery of bank wealth management products[23] - Cash flow from operating activities is ¥373,236,975.23, down from ¥424,359,609.02 in the previous period, a decline of 12.1%[100] - The total cash and cash equivalents at the end of the period amounted to 205,617,539.82, down from 898,613,468.29 in the previous period, a decrease of approximately 77.1%[106] - The company reported total current assets of CNY 2,374.81 million, an increase from CNY 2,263.68 million in the previous period[67] - The company's cash and cash equivalents stood at CNY 1,249.08 million, compared to CNY 809.52 million in the previous period, indicating a significant increase[67] Shareholder and Equity Information - Total assets at the end of the reporting period were ¥2,943,004,366.18, an increase of 3.54% from ¥2,842,499,295.08 at the end of the previous year[9] - Net assets attributable to shareholders increased by 2.05% to ¥2,622,200,229.49 from ¥2,569,491,637.53 at the end of the previous year[9] - The top ten shareholders held a total of 56.85% of the shares, with the largest shareholder holding 16.05%[13] - Total liabilities as of March 31, 2020, were CNY 320.80 million, up from CNY 273.01 million in the previous period[73] - The total equity attributable to shareholders reached CNY 2,616,752,820.45, up from CNY 2,565,274,189.03, marking a rise of 2.0%[83] Research and Development - Research and development efforts are focused on enhancing the effectiveness of the main product, Tanreqing injection, with ongoing projects showing progress[29] - The company is conducting clinical research on a new drug, Dinggui Oil Soft Capsule, for treating irritable bowel syndrome, currently in Phase III clinical trials[37] - The company is in Phase II clinical research for its Baolung Granules, aimed at treating chronic obstructive pulmonary disease[37] - Research and development expenses were CNY 8,715,823.47, down from CNY 10,271,177.81, a decrease of 15.2%[86] - The company is focusing on optimizing its product structure, particularly for its main product, Phlegm Heat Injection, which accounts for over 90% of its main business revenue[39] Government and Subsidies - The company received government subsidies amounting to ¥1,530,370.41 during the reporting period[9] - Other income increased by 178.21% year-on-year, mainly due to an increase in government subsidies[24] Investment and Projects - The company has invested 99.74% of the promised investment project for the modernization of traditional Chinese medicine, totaling 24.986 million yuan out of a promised 25.050 million yuan[49] - The second phase of the modernization of traditional Chinese medicine project has seen an investment completion rate of 86.85%, with 6.948 million yuan invested out of 8.000 million yuan promised[49] - The company has allocated 1.735 million yuan for the purchase of land use rights from the raised funds, achieving a 100% investment completion rate[49] - The company plans to use 15 million yuan of raised funds for purchasing raw materials and clinical trial approvals for "Dinggui Oil Soft Capsules" and "Bear Gallbladder Pills" as of March 31, 2020[56] Risks and Challenges - The company is facing significant industry risks due to policy changes affecting the pharmaceutical sector, which may impact its operations[38] - The company is addressing the risk of reliance on a single product by enhancing sales efforts for existing products and improving R&D capabilities[39]

证券代码：300039 证券简称：上海凯宝 公告编号：2019-073 上海凯宝药业股份有限公司 关于参加上海辖区上市公司投资者集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流工作，上海凯宝药业股份有限公司（以下简 称"公司"）将参加由上海上市公司协会、上证所信息网络有限公司共同举办的"2019 年上海辖区上市公司投资者集体接待日"活动，现将有关事项公告如下： 本次集体接待日活动将在上证所信息网络有限公司提供的平台，采取网络远程 的方式举行，投资者可以登录"上证路演中心"网站（http://roadshow.sseinfo.com） 或关注微信公众号：上证路演中心（sse_roadshow），参与公司本次投资者集体接待 日活动，活动时间为 2019 年 9 月 26 日（星期四）下午 15:00 至 17:00。届时公司 董事、总经理王国明先生，财务总监、董事会秘书任立旺先生，将通过网络在线交 流形式与投资者就公司治理、发展战略、经营状况和可持续发展等投资者关注的问 题进行沟通。 欢迎广大投资者积极参与！ 特 ...

Financial Performance - Total revenue for the first half of 2019 was ¥787,880,812.29, a decrease of 13.10% compared to ¥906,650,078.41 in the same period last year[19]. - Net profit attributable to shareholders was ¥152,997,695.51, down 16.46% from ¥183,136,931.33 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was ¥145,002,115.27, representing an 18.18% decrease from ¥177,217,844.83 in the same period last year[19]. - Basic earnings per share decreased by 16.42% to ¥0.1435 from ¥0.1717 in the same period last year[19]. - The operating profit was 180.45 million yuan, down 16.70% year-on-year[42]. - The company achieved operating revenue of 787.88 million yuan, a decrease of 13.10% compared to the same period last year[42]. - The total profit for the first half of 2019 was ¥180,924,512.29, a decrease of 16.5% from ¥216,622,251.56 in the first half of 2018[170]. - The company's total comprehensive income for the first half of 2019 was ¥152,997,695.51, down from ¥183,136,931.33 in the first half of 2018[171]. Cash Flow and Assets - Operating cash flow net amount increased by 17.64% to ¥127,306,030.84, compared to ¥108,215,232.60 in the previous year[19]. - The net cash generated from operating activities increased by 17.64% to RMB 127,306,030.84, primarily due to enhanced collection efforts on accounts receivable[53]. - The net cash generated from investment activities rose significantly by 86.19% to RMB 223,396,179.50, mainly due to the redemption of external investments[54]. - The company's cash and cash equivalents increased by 63.77% to RMB 198,091,195.09 compared to the previous year[54]. - Total assets at the end of the reporting period were ¥2,808,910,905.02, an increase of 2.24% from ¥2,747,388,592.99 at the end of the previous year[19]. - The total amount of raised funds is RMB 97,375.76 million, with a net amount after expenses of RMB 97,375.76 million[70]. - The cash and cash equivalents at the end of the period amounted to CNY 744,658,671.05, up from CNY 702,473,670.33 at the end of the first half of 2018, representing a growth of 6.0%[180]. Research and Development - The company aims to accelerate the development of new products and technologies, focusing on the modernization of traditional Chinese medicine and expanding into the health technology sector[33]. - The company is actively advancing the secondary development of its main product, Tanreqing, and is involved in significant new drug creation projects[43]. - The company obtained 2 invention patents, 2 design patents, and 4 utility model patents during the reporting period, enhancing its intellectual property protection[44]. - Research and development expenses decreased by 26.57% to RMB 26,128,105.51, down from RMB 35,584,054.62 in the previous year[53]. Market and Product Strategy - The main product, Tanreqing injection, is a patented product and a national protected traditional Chinese medicine, recognized for its effectiveness in treating major epidemic diseases[28]. - The company is focusing on expanding its product portfolio in key therapeutic areas such as respiratory, cardiovascular, digestive, and oncology[43]. - The company is actively pursuing market expansion in the health sector, aligning with the national health strategy and focusing on the development of health-related products[29]. - The company is actively enhancing its R&D capabilities to diversify its product offerings and reduce dependence on Tanreqing injection, while also seeking new product introductions and acquisition opportunities[94]. Corporate Governance and Compliance - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has not reported any significant litigation or arbitration matters during the reporting period[104]. - The financial report for the first half of 2019 was not audited[157]. - The company maintains a good integrity status, with no significant debts or court judgments pending[107]. Environmental and Social Responsibility - The company has established two wastewater treatment facilities with a capacity of 1,000 tons per day to ensure compliance with discharge standards[120]. - The company donated a total of 15,000 RMB to a local village and participated in charitable activities, contributing an additional 50,000 RMB in the first half of 2019[126]. - The company plans to continue its commitment to poverty alleviation and social responsibility initiatives, leveraging its public listing for further development[129]. Future Outlook - The company plans to focus on expanding its market presence and developing new products to enhance revenue streams in the upcoming quarters[193]. - Future outlook remains cautious with no specific guidance provided for upcoming quarters[189].

Financial Performance - The company's total revenue for 2018 was ¥1,500,676,455.17, representing a decrease of 4.41% compared to ¥1,569,916,033.26 in 2017[14] - The net profit attributable to shareholders for 2018 was ¥226,812,437.14, down 16.71% from ¥272,304,671.80 in the previous year[14] - The net profit after deducting non-recurring gains and losses was ¥238,853,501.73, a decrease of 8.28% from ¥260,420,033.84 in 2017[14] - The basic earnings per share for 2018 was ¥0.2117, down 16.69% from ¥0.2541 in 2017[14] - The total operating revenue for 2018 was ¥1,500,676,455.17, representing a decrease of 4.41% compared to ¥1,569,916,033.26 in 2017[54] - Operating profit was CNY 27,493.41 million, down 17.34% year-on-year[41] - Net profit attributable to shareholders was CNY 22,681.24 million, reflecting a decline of 16.71% from the previous year[41] Assets and Liabilities - The total assets at the end of 2018 were ¥2,747,388,592.99, an increase of 2.53% from ¥2,679,724,094.17 at the end of 2017[14] - The net assets attributable to shareholders increased by 5.06% to ¥2,485,128,992.94 from ¥2,365,465,935.80 in 2017[14] - The company’s deferred tax assets increased by 90.36% due to changes in the fair value of financial assets[31] - Prepayments decreased by 37.77% compared to the beginning of the year, primarily due to reduced advance payments for raw materials and equipment[30] - Other receivables decreased by 36.98% compared to the beginning of the year, mainly due to a reduction in accrued interest on bank deposits and employee advances[30] - Long-term equity investments decreased by 100% due to impairment provisions[30] Cash Flow and Dividends - The net cash flow from operating activities was ¥262,361,430.99, reflecting a 6.76% increase from ¥245,758,441.22 in the previous year[14] - The company plans to distribute a cash dividend of ¥1.00 per 10 shares (tax included) to all shareholders[4] - The cash dividend for 2018 is also proposed to be RMB 1 per 10 shares, pending approval at the annual shareholders' meeting[120] - The cash dividend payout ratio for 2017 was 78.70%, reflecting a commitment to returning value to shareholders[124] Research and Development - R&D investment totaled CNY 4,749.98 million, accounting for 3.17% of total revenue[43] - The company is actively pursuing research and development, with a new R&D building completed and entering the acceptance phase, aimed at enhancing innovation capabilities[28] - The company has increased R&D investment to enhance core competitiveness, focusing on the efficacy evaluation of its main product, Tanreqing injection[49] - The company is focusing on the development of new products in the health sector, including drug cosmetics and disinfectants[32] - Research and development expenses in 2018 amounted to ¥47,351,543.29, a decrease of 26.80% compared to 2017[64] Product Development and Market Strategy - The main product, Tanreqing injection, is a patented product recognized as a national strategic reserve drug, contributing significantly to the treatment of respiratory infections[23] - The company has established a strong product line in three major areas: respiratory, cardiovascular, and digestive health, enhancing its competitive edge[22] - The subsidiary, Xinyi Pharmaceutical, has developed Qishen capsules, a national new drug for treating coronary heart disease, showcasing the company's innovation in cardiovascular treatments[24] - The company is currently conducting clinical research on seven new drug projects, including the "Dinggui Oil Soft Capsule" and "Shufeng Zhitong Capsule," both in Phase III clinical trials[51] - The company is exploring new strategies for market expansion and product development to enhance its core competitiveness[51] Market Performance and Challenges - The company faced a net loss of ¥11,638,984.32 in the fourth quarter of 2018, contrasting with profits in the first three quarters[16] - The revenue from injections was ¥1,413,967,469.10, accounting for 94.23% of total revenue, with a decrease of 4.34% from the previous year[54] - The revenue from the South China region decreased significantly by 15.97% to ¥264,604,109.08, compared to ¥314,905,406.40 in 2017[55] - The company has focused on marketing strategies to stabilize sales and expand market presence amid healthcare reforms, enhancing the promotion of its main product, Xiongdan Diban[44] - The company is actively seeking new product introductions and acquisition opportunities to diversify its product line and reduce reliance on Tanreqing[111] Corporate Governance and Compliance - The company emphasizes investor relations management, maintaining good communication through various channels, including online performance briefings and investor meetings[46] - The company received an "A" rating in the Shenzhen Stock Exchange's annual information disclosure assessment, reflecting its commitment to transparency and investor relations[47] - The company has maintained a good integrity status without any unfulfilled court judgments or significant debts due during the reporting period[134] - The company has not engaged in any share buybacks during the reporting period, which would affect the dividend distribution[124] Environmental and Social Responsibility - The company has established wastewater treatment facilities with a capacity of 1,000 tons per day, ensuring compliance with discharge standards[163] - The company has received ISO 14001:2015 certification for its environmental management system, demonstrating its commitment to environmental protection[170] - The company donated a total of RMB 50,000 for poverty alleviation activities in May 2018, along with additional donations of RMB 10,000 and RMB 100,000 from its subsidiary for various charitable causes[159] - The company has invested RMB 702,428.05 in material support for poverty alleviation efforts[160] Shareholder Structure and Management - The total number of shares outstanding is 1,071,493,800, with 720,391,858 shares classified as unrestricted and 351,101,942 shares as restricted[180] - Major shareholder Mu Laian holds 321,580,740 shares, representing 30.01% of the total shares, with 12,500,000 shares pledged[186] - The company has a total of 10 major shareholders, with the top four shareholders being related parties, indicating potential influence on corporate governance[186] - The company has appointed Ren Liwang as the new board secretary effective October 25, 2018[194] - The company continues to maintain a strong leadership team with diverse professional backgrounds in the pharmaceutical industry[195][196]